Potential repurposing of oncology drugs for the treatment of Alzheimers diseaseReport as inadecuate

Potential repurposing of oncology drugs for the treatment of Alzheimers disease - Download this document for free, or read online. Document in PDF available to download.

BMC Medicine

, 11:82

First Online: 26 March 2013Received: 12 February 2013Accepted: 26 March 2013DOI: 10.1186-1741-7015-11-82

Cite this article as: Araki, W. BMC Med 2013 11: 82. doi:10.1186-1741-7015-11-82


Alzheimer-s disease AD is the most common form of neurodegenerative dementia, affecting about 30 million people worldwide. Despite recent advances in understanding its molecular pathology, no mechanism-based drugs are currently available that can halt the progression of AD. Because amyloid-β-peptide Aβ, a primary component of senile plaques, is thought to be a central pathogenic culprit, several disease-modifying therapies are being developed, including inhibitors of Aβ-producing proteases and immunotherapies with anti-Aβ antibodies. Drug repositioning or repurposing is regarded as a complementary and reasonable approach to identify new drug candidates for AD. This commentary will discuss the clinical relevance of an attractive candidate compound reported in a recent paper by Hayes et al. BMC Medicine 2013 as well as perspectives regarding the possible repositioning of oncology drugs for the treatment of AD.

See related research article here http:-www.biomedcentral.com-1741-7015-11-81

KeywordsAlzheimer-s disease amyloid β-peptide disease-modifying drugs drug repositioning AbbreviationsAβamyloid β-peptide

ADAlzheimer-s disease

ApoEapolipoprotein E

APPamyloid precursor protein

BCNU1,3 bis2-chloroethyl-1-nitrosourea or carmustine

RARsretinoic acid receptors

RXRsretinoid X receptors

TGFtransforming growth factor

Download fulltext PDF

Author: Wataru Araki

Source: https://link.springer.com/

Related documents